Abstract
Angiogenesis is essential for tumor growth and blocking this process might be a valid tool for the control of cancer growth. We showed previously that tumor angiogenesis in integrin α1-null mice is reduced compared to that of wild type animals and that over-expression of matrix metalloproteinase 9 (MMP-9) in the α1-null and consequent generation of angiostatin (an inhibitor of endothelial cell growth) from circulating plasminogen was implicated in the mechanism of tumor inhibition. Our findings suggested that secretion of excess MMPs generates inhibitors of endothelial cell proliferation, including but not necessarily limited to angiostatin, resulting ultimately in auto-inhibition of angiogenesis. Thus MMP inhibitors used as anti-tumor drugs might in fact cause a paradoxical increase in tumor angiogenesis and tumor growth. In order to determine whether MMP-9 expression was directly involved in the regulation of tumor growth, we specifically inhibited or enhanced MMP-9 synthesis in vitro and in vivo, and subsequently analysed primary endothelial cell proliferation and angiostatin synthesis, as well as tumor vascularization and development. We provide evidence that reduction of plasma levels of MMP-9 in either normal or integrin α1-null mice leads to decreased synthesis of angiostatin and consequent increased tumor growth and vascularization. In contrast, specifically enhancing MMP-9 expression in vivo caused a reduction in tumor vascularization. These findings are the opposite to other studies suggesting a pro-tumorigenic role for MMP-9, and may account for some of the recently observed failures of anti MMP therapy in tumor treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agouron. 2000 http://www.agouron.com/Pages/press_releases/pr080400.html
Axisa B, Naylor AR, Bell PR, Thompson MM . 2000 J. Chromatogr. B. Biomed. Sci. Appl. 744: 359–365
Bayer Corp. USA. 1999 http:www.bayerus.com/new/1999/09.99ud.htiml
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D . 2000 Nat. Cell Biol. 2: 737–744
Bernhard EJ, Gruber SB, Muschel RJ . 1994 Proc. Natl. Acad. Sci. USA 91: 4293–4297
Bettany JT, Wolowacz RG . 1998 Adv. Dent. Res. 12: 136–143
Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA . 1998 Cell 92: 391–400
Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD . 1998 J. Immunol. 161: 6845–6852
Curci JA, Mao D, Bohner DG, Allen BT, Rubin BG, Reilly JM, Sicard GA, Thompson RW . 2000 J. Vasc. Surg. 31: 325–342
Fife RS, Sledge Jr GW . 1995 J. Lab. Clin. Med. 125: 407–411
Fife RS, Sledge Jr GW . 1998 Adv. Dent. Res. 12: 94–96
Forget MA, Desrosiers RR, Beliveau R . 1999 Can. J. Physiol. Pharmacol. 77: 465–480
Gardner H, Broberg A, Pozzi A, Laato M, Heino J . 1999 J. Cell. Sci. 112: 263–272
Hanemaaijer R, Visser H, Koolwijk P, Sorsa T, Salo T, Golub LM, van Hinsbergh VW . 1998 Adv. Dent. Res. 12: 114–118
Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ . 1998 Cell 95: 365–377
Jia MC, Schwartz MA, Sang OX . 2000 Adv. Exp. Med. Biol. 476: 181–194
Kleiner DE, Stetler-Stevenson WG . 1999 Cancer Chemother. Pharmacol. 43: S42–S51
Kruger A, Soeltl R, Sopov I, Kopitz C, Arlt M, Magdolen V, Harbeck N, Gansbacher B, Schmitt M . 2001 Cancer Res. 61: 1272–1275
Lokeshwar BL . 1999 Ann. NY Acad. Sci. 878: 271–289
Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA . 2000 Proc. Natl. Acad. Sci. USA 97: 2202–2207
Pozzi A, Wary KK, Giancotti FG, Gardner HA . 1998 J. Cell Biol. 142: 587–594
Ramos-DeSimone N, Moll UM, Quigley JP, French DL . 1993 Hybridoma 12: 349–363
Ravanti L, Heino J, Lopez-Otin C, Kahari VM . 1999 J. Biol. Chem. 274: 2446–2455
Rivas MJ, Arii S, Furutani M, Harada T, Mizumoto M, Nishiyama H, Fujita J, Imamura M . 1998 Hepatology 28: 986–993
Sang QX . 1998 Cell Res. 8: 171–177
Sayers TJ, Brooks AD, Lee JK, Fenton RG, Komschlies KL, Wigginton JM, Winkler-Pickett R, Wiltrout RH . 1998 J. Immunol. 161: 3957–3965
Seftor RE, Seftor EA, De Larco JE, Kleiner DE, Leferson J, Stetler-Stevenson WG, McNamara TF, Golub LM, Hendrix MJ . 1998 Clin. Exp. Metastasis 16: 217–225
Sipos EP, Tamargo RJ, Weingart JD, Brem H . 1994 Ann. NY Acad. Sci. 732: 263–272
Smith Jr GN, Mickler EA, Hasty KA, Brandt KD . 1999 Arthritis Rheum. 42: 1140–1146
Sobrin L, Liu Z, Monroy DC, Solomon A, Selzer MG, Lokeshwar BL, Pflugfelder SC . 2000 Invest. Ophthalmol. Vis. Sci. 41: 1703–1709
Soloway PD, Alexander CM, Werb Z, Jaenisch R . 1996 Oncogene 13: 2307–2314
Sorsa T, Ramamurthy NS, Vernillo AT, Zhang X, Konttinen YT, Rifkin BR, Golub LM . 1998 J. Rheumatol. 25: 975–982
Standker L, Schrader M, Kanse SM, Jurgens M, Forssmann WG, Preissner KT . 1997 FEBS Lett. 420: 129–133
van den Bogert C, Dontje BH, Kroon AM . 1985 Leuk. Res. 9: 617–623
Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z . 1998 Cell 93: 411–422
Xiang R, Lode HN, Dreier T, Gillies SD, Reisfeld RA . 1998 Cancer Res. 58: 3918–3925
Acknowledgements
We thank Vito Quaranta and Jim Quigley for valuable suggestions. We specially thank Jorge Capdevila and Dao-Wen Wang (Vanderbilt University) for their precious help with HPLC analysis. This work was supported by NIAMS AR44514 and a grant from the Scleroderma Foundation, both to H Gardner.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pozzi, A., LeVine, W. & Gardner, H. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21, 272–281 (2002). https://doi.org/10.1038/sj.onc.1205045
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205045
Keywords
This article is cited by
-
Expression deregulation of matrix metalloproteinases and vasoconstriction related genes in Pakistani females with abnormal uterine bleeding
BMC Women's Health (2022)
-
Cancer-Specific Survival Stratification Derived from Tumor Expression of Tissue Inhibitor of Metalloproteinase-2 in Non-Metastatic Renal Cell Carcinoma
Pathology & Oncology Research (2019)
-
Gr-1+CD11b+ cells facilitate Lewis lung cancer recurrence by enhancing neovasculature after local irradiation
Scientific Reports (2014)
-
MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis
Oncogene (2012)
-
MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not
British Journal of Cancer (2008)